Aptevo Therapeutics and Alligator Bioscience to present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting.
M2 EQUITYBITES-November 11, 2019-Aptevo Therapeutics and Alligator Bioscience to present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Aptevo Therapeutics Inc (Nasdaq: APVO), a biotechnology company focused on developing novel immuno -oncology and haematology therapeutics, and Alligator Bioscience (STO:ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumour-directed immunotherapy, announced on Friday that new preclinical data for ALG.APV-527 is being presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting at the National Harbor, Maryland, being held between 6 November 2019 to 10 November 2019.
ALG.APV-527 is a novel immunotherapeutic candidate intended for the treatment of a variety of 5T4-positive solid tumours. It is designed to induce signaling through the co-stimulatory receptor 4-1BB (CD137), which is present on activated cytotoxic T cells and natural killer (NK) cells. Once activated, it is designed to promote potent and selective tumour-directed immune activation in the presence of the tumour associated antigen, 5T4, which is present on many different types of solid tumours.
According to the companies, this preclinical data presented at SITC will show that ALG.APV-527 selectively enhances T cell and NK cell responses in the presence of 5T4 in vitro and displays potent and sustained tumour suppression in vivo.
The Alligator/Aptevo poster presentation, entitled 'Potent Tumour-Directed T Cell Activation and Tumour Inhibition Induced by a 4-1BB x 5T4 ADAPTIR Bispecific Antibody' is being presented on 9 November 2019 from 7:00 hours to 8:30 hours ET.
ALG.APV-527 is a bispecific antibody (4-1BB x 5T4) intended for tumour-directed treatment of solid cancers. ALG.APV-527 was built using Aptevo's ADAPTIR bispecific platform and combines binding domains sourced from the ALLIGATOR -GOLD human scFv library. The ALG.APV-527 bispecific antibody consists of two parts, one part activating tumour-specific T cells through the co-stimulatory receptor 4-1BB, the other part binding to the 5T4 protein displayed on the surface of tumour cells. This enables the immune-activating effect of ALG.APV-527 to be directed specifically to the tumour and not against normal tissue.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 11, 2019|
|Previous Article:||Westlake Chemical Partners welcomes Randy Woelfel to board.|
|Next Article:||Ares Commercial names Bryan Donohoe as new CEO succeeding Jamie Henderson.|